Hengrui Pharmaceuticals(01276.HK): Injection SHR-3079 Obtains Clinical Trial Approval Notice

NewTimeSpace · 2026/07/13 21:53 · By Jiayi Sun

NewTimeSpace News: Hengrui Pharmaceuticalsannounced on 13 July that its subsidiary Suzhou Shengdiya received the Clinical Trial Approval Notice for Injection SHR-3079 issued and approved by the National Medical Products Administration (NMPA), authorizing clinical trials for indications of adult systemic lupus erythematosus and adult rheumatoid arthritis.

NewTimeSpace News: On 13 July 2026, Hengrui Pharmaceuticals(01276.HK) issued an announcement that Suzhou Shengdiya Biomedicine Co., Ltd., its subsidiary, has obtained the Clinical Trial Approval Notice for Injection SHR-3079 from the NMPA.

The drug is an innovative medicine independently developed by the Company, intended for the treatment of adult systemic lupus erythematosus and adult rheumatoid arthritis. Meanwhile, Phase I clinical trials for its application in B-cell non-Hodgkin’s lymphoma are underway.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Hengrui Pharmaceuticals 01276.HK